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Abstract
Background: We have previously developed a test for the diagnosis and prognostic assessment
of the severe acute respiratory syndrome (SARS) based on the detection of the SARS-coronavirus
RNA in serum by real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR).
In this study, we evaluated the feasibility of automating the serum RNA extraction procedure in
order to increase the throughput of the assay.
Methods: An automated nucleic acid extraction platform using the MagNA Pure LC instrument
(Roche Diagnostics) was evaluated. We developed a modified protocol in compliance with the
recommended biosafety guidelines from the World Health Organization based on the use of the
MagNA Pure total nucleic acid large volume isolation kit for the extraction of SARS-coronavirus
RNA. The modified protocol was compared with a column-based extraction kit (QIAamp viral
RNA mini kit, Qiagen) for quantitative performance, analytical sensitivity and precision.
Results:  The newly developed automated protocol was shown to be free from carry-over
contamination and have comparable performance with other standard protocols and kits designed
for the MagNA Pure LC instrument. However, the automated method was found to be less
sensitive, less precise and led to consistently lower serum SARS-coronavirus concentrations when
compared with the column-based extraction method.
Conclusion: As the diagnostic efficiency and prognostic value of the serum SARS-CoV RNA RT-
PCR test is critically associated with the analytical sensitivity and quantitative performance
contributed both by the RNA extraction and RT-PCR components of the test, we recommend the
use of the column-based manual RNA extraction method.
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Background
The severe acute respiratory syndrome (SARS), etiologi-
cally related to a newly emerged coronavirus (SARS-CoV)
[1], caused an epidemic in 2003 with reported cases in 29
countries around the world [2]. A factor that is important
in the effective control of an epidemic involves the early
identification and isolation of infected individuals [3]. We
have previously reported the development of a diagnostic
test based on the detection of the SARS-CoV RNA in
serum/plasma by real-time quantitative reverse tran-
scriptase polymerase chain reaction (RT-PCR) [4,5].
Eighty percent of infected individuals were shown to be
positive by the test on the first day of hospital admission
with no false-positive results [4,5]. The serum SARS-CoV
RNA concentration detected upon admission has also
been shown to be predictive of the requirement for subse-
quent intensive care [4]. The approach has been demon-
strated to be useful for serial monitoring of treatment
efficacy [6].
The analytical protocol that had been developed involved
the use of a manual RNA extraction method. As the
demand for diagnostic testing at times of infectious dis-
ease outbreaks would be high, strategies that may enhance
the throughput of analytical procedures would be advan-
tageous. In this study, we assessed the feasibility of auto-
mating the RNA extraction procedure of the serum SARS-
CoV RNA test by evaluating the performance of an auto-
mated extraction system.
Methods
The aim of the study was to compare the efficacy of SARS-
CoV RNA extraction based on the use of the QIAamp viral
RNA mini kit (Qiagen, Hilden, Germany) with protocols
adapted for the MagNA Pure LC instrument (Roche Diag-
nostics, Basel, Switzerland). The former protocol is a man-
ual column-based method based on silica-adsorption. On
the other hand, the MagNA Pure LC instrument extracts
nucleic acids from biological specimens based on mag-
netic bead separation. The principle and general setup of
the instrument had been previously described [7]. The
main objective of this study was to compare the resultant
analytical sensitivity and quantitative performance of the
serum SARS-CoV RNA test when either the manual or
automated extraction protocol was used.
Development of an automated protocol for SARS-CoV 
RNA extraction
According to the manufacturer's information, 2 kits,
namely the MagNA Pure LC total nucleic acid isolation kit
(Roche Diagnostics) and the MagNA Pure total nucleic
acid large volume isolation kit (Roche Diagnostics), are
recommended for use with the MagNA Pure LC instru-
ment for the extraction of viral DNA or RNA from serum
or plasma. The main differences between the two kits lie
in the starting sample volume and whether an external
lysis protocol is available. The former kit processes 200 µL
of serum and is compatible with the use of an external
lysis protocol preinstalled in the accompanying software
(MagNA Pure LC Software v.3.0, Roche Applied Science)
of the MagNA Pure LC instrument. The latter kit, however,
processes 1000 µL of serum and no external lysis protocol
had been predefined. External lysis is a processing step
whereby lysis buffer can be added to clinical specimens
manually prior to the transfer of the sample and buffer
mixture to the automated instrument for further down-
stream processing. External lysis is a desirable step for the
processing of potentially infectious specimens whereby
the specimens could be processed according to the recom-
mended biosafety precautions until the pathogens are
lysed and the specimen rendered safe for further process-
ing by the MagNA Pure LC instrument.
However, the sensitive detection of SARS-CoV RNA from
serum may be dependent on a large starting volume of
serum. Therefore, we evaluated an in-house modification
of the manufacturer's protocol for the "large volume" kit
with the addition of an external lysis step. To minimise
the infectious risk to the laboratory personnel, all analyses
were performed using aliquots of a SARS-CoV culture iso-
late that had been inactivated by procedures previously
described [8]. Inactivated SARS-CoV was spiked into
transport medium so that the resultant mixture contained
108 copies/mL of the virus. Viral RNA was extracted from
aliquots of this mixture in triplicate both according to the
standard as well as modified protocols for the large vol-
ume kit. For the standard protocol, laboratory personnel
were only involved with the initial transfer of 1000 µL of
each specimen to individual sample cartridges placed
inside the instrument after which proteinase K and buff-
ers, including 450 µL of lysis buffer, were added by the
instrument in a sequential and automated fashion. For
the modified protocol, 310 µL of lysis buffer was first
added to 690 µL of specimen in a biosafety cabinet to
make up a final volume of 1000 µL. After vortexing, the
mixture was transferred in ice to the sample cartridges on
the MagNA Pure LC instrument. The instrument was then
activated to run as per the standard protocol. The exter-
nally-added lysis buffer (310 µL) when mixed with the
volume of lysis buffer pre-loaded on the MagNA Pure LC
instrument (450 µL) amounts to a total of 860 µL of lysis
buffer for 690 µL of specimen and thus contributes to a
lysis buffer:sample ratio which largely resembles that
adopted in the external lysis protocol of the total nucleic
acid isolation kit. All viral RNA preparations extracted in
this study were quantified using a real time quantitative
one-step RT-PCR assay targeting the Nucleocapsid-gene of
the SARS-CoV as previously described [4]. Briefly, the
assay involves the use of the EZ rTth RNA PCR reagent set
(Applied Biosystems, Foster City, California) on anBMC Infectious Diseases 2006, 6:20 http://www.biomedcentral.com/1471-2334/6/20
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Applied Biosystems 7700 Sequence Detector. 12 µL of
extracted viral RNA was used for amplification in a reac-
tion volume of 25 µL.
The modified large volume protocol with the external
lysis step was further compared with the external lysis pro-
tocol of the total nucleic acid isolation kit using a trans-
port medium mixture containing 106  copies/mL of
inactivated SARS-CoV. Quadruplicate extractions were
performed. We also assessed the analytical sensitivities of
both protocols by comparing the detection rates for aliq-
uots of transport medium diluted to contain 10, 102 and
103 copies/mL of inactivated SARS-CoV, respectively. Five
extractions were performed for each concentration. We
then addressed the possibility of carry-over contamina-
tion within the MagNA Pure LC instrument by introduc-
ing nine aliquots of transport medium containing
inactivated SARS-CoV ranging from 102 to 107 copies/mL
alternating with aliquots of plain transport medium on
the instrument and using the modified large volume pro-
tocol for extraction.
Comparison of the automated and manual protocols for 
SARS-CoV RNA detection in serum
The modified large volume protocol was selected for fur-
ther comparison with the performance of the column-
based manual method. The manual extraction method
was performed according to the manufacturer's instruc-
tions. Transport medium and pooled sera were mixed
with serially diluted aliquots of inactivated SARS-CoV to
produce samples containing SARS-CoV with concentra-
tions ranging from 103 to 109 copies/mL. The pooled sera
were first confirmed to be negative for SARS-CoV by the
quantitative RT-PCR assay. Viral RNA was extracted from
the serial samples by both the automated and manual
methods and SARS-CoV RNA concentrations were deter-
mined by the quantitative RT-PCR test [4]. Viral RNA con-
centrations were compared using Passing-Bablok
regression [9].
We next compared the effects of the RNA extraction meth-
ods on the overall assay sensitivity. Pooled sera spiked
with 10, 102 and 103 copies/mL of inactivated SARS-CoV
were extracted by both methods. Ten replicate extractions
were performed for each concentration. The detection rate
at each concentration was compared amongst the two
extraction methods. Lastly, we assessed the reproducibil-
ity of both protocols by performing replicate analyses (n
= 10) of two pooled sera containing 103 and 105 copies/
mL of inactivated SARS-CoV, respectively. The mean and
coefficient of variation were determined and compared.
Statistical analysis
Statistical analysis was performed using the MedCalc soft-
ware version 8.0.
Results
Evaluation of the modified protocol of the MagNA Pure 
LC total nucleic acid large volume kit and comparisons 
with the MagNA Pure LC total nucleic acidisolated kit
Triplicate viral RNA extractions of the transport medium
mixture containing 108 copies/mL inactivated SARS-CoV
by the standard protocol of the large volume kit yielded
SARS-CoV RNA concentrations of 3.11 × 108, 3.14 × 108
and 3.17 × 108 copies/mL. By incorporating an external
lysis procedural step, the modified protocol yielded 4.92
× 108, 5.20 × 108 and 5.48 × 108 copies/mL. As the modi-
fied large volume protocol yielded results comparable to
that of the standard large volume protocol, the former was
used for further comparison with the external lysis proto-
col of the "total nucleic acid" kit which uses a starting
sample volume of 200 µL. Quadruplicate analysis of the
transport medium mixture containing 106  copies/mL
SARS-CoV yielded 6.57 × 106, 7.41 × 106, 1.34 × 107 and
6.17 × 107 copies/mL when the large volume kit was used.
When the total nucleic acid kit was used, the results were
8.20 × 106, 8.40 × 106, 1.05 × 107 and 6.80 × 107 copies/
mL.
The analytical sensitivities contributed by the two kits
were next compared. Viral RNA extracted by both kits was
detectable in all five replicates when the sample contained
103 copies/mL SARS-CoV. However, when the sample
contained 102 copies/mL SARS-CoV, the large volume kit
yielded positive detection in all five replicates, while
SARS-CoV was only detected from three replicates when
extracted by the total nucleic acid kit. Furthermore, when
the sample contained 10 copies/mL SARS-CoV, the large
volume kit yielded positive detection in four replicates,
while viral RNA extractions from the total nucleic acid kit
was only positive in one replicate. These data suggest that
the modified protocol of the large volume kit has compa-
rable performance with the total nucleic acid kit for the
extraction of samples containing high SARS-CoV concen-
tration, but enabled more sensitive detection when sam-
ples containing low levels of SARS-CoV were extracted. By
aligning samples positive and negative for SARS-CoV in
an alternating manner for extraction by the modified pro-
tocol of the large volume kit, there was no evidence of
carry-over contamination. All the negative samples were
indeed tested negative regardless of the magnitude of the
SARS-CoV concentrations (ranging from 102 to 107 cop-
ies/mL) in the adjacent wells. Thus, the modified protocol
of the large volume kit was selected for further evaluation
for SARS-CoV RNA extraction from serum.
SARS-CoV RNA detection in serum extracted by the 
automated and manual methods
Serially diluted inactivated SARS-CoV isolate in transport
medium was extracted by both the column-based manual
method and the MagNA Pure LC instrument using theBMC Infectious Diseases 2006, 6:20 http://www.biomedcentral.com/1471-2334/6/20
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modified large volume protocol with external lysis. The
SARS-CoV concentrations from both series of viral RNA
extracts were compared using the Passing-Bablok regres-
sion method [9]. The Passing-Bablok procedure is a linear
regression method developed for method comparison
evaluations without dependence on the assignment of
either one of the two compared methods as the reference.
Furthermore, it makes no assumption on the distribution
of sample data and measurement errors of the compared
methods. The Passing-Bablok comparison of the SARS-
CoV concentrations in transport medium as extracted by
the two methods is presented in Figure 1A. The quantita-
tive relationship can be described by y = -207.0 + 0.305x
(95% confidence intervals for the slope, 0.260 to 0.407;
and y-intercept, -661.7 to 128.6). The slope of the regres-
sion line being less than 1 suggests there is a proportional
negative bias in SARS-CoV concentration extracted by the
automated method when compared with the manual
method.
A similar comparison was performed for serially diluted
SARS-CoV mixture in pooled sera. Figure 1B illustrates the
Passing-Bablok comparison. The quantitative relationship
can be described by y = -62.4 + 0.304x (95% confidence
intervals for the slope, 0.252 to 0.442; and y-intercept, -
205.6 to 380.4). The slope of the regression line being less
than 1 also suggests the presence of a proportional nega-
tive bias in serum SARS-CoV concentration extracted by
the automated method when compared with the manual
method.
The effect of the automated and manual methods on the
overall assay sensitivity was next compared. Results for
this part of the study are summarized in Table 1. SARS-
CoV RNA was detectable from all ten replicates when the
serum aliquots containing 103 copies/mL SARS-CoV were
extracted by either methods. For serum containing 102
copies/mL SARS-CoV, nine and seven of the replicates
were tested positive when viral RNA was extracted by the
manual and automated methods, respectively. For serum
containing 10 copies/mL SARS-CoV, four of the replicates
were positive when extracted by the manual method and
only one was positive when the replicates were extracted
by the automated method.
To assess the effects of the two extraction protocols on the
precision or reproducibility of the quantitative SARS-CoV
RT-PCR assay, RNA extractions by each protocol were
repeated 10 times for serum aliquots containing SARS-
CoV concentration well above the detection limit of the
assay, namely 103 and 105 copies/mL. Results for this part
of the study are summarized in Table 1. For serum SARS-
CoV concentration at 103 copies/mL, the overall assay
coefficient of variation (standard deviation/mean ×
100%) was 45.3% and 76.9% when RNA extractions from
the manual and automated methods were quantified,
respectively. For serum SARS-CoV concentration at 105
copies/mL, the assay coefficient of variation was 47.4%
for the manual RNA extraction and 51.0% when auto-
mated RNA extraction was used.
Discussion
In an attempt to increase the throughput of a previously
developed quantitative serum SARS-CoV RNA RT-PCR
assay [4,5], we evaluated the feasibility of automating the
RNA extraction procedure through the use of the MagNA
Pure LC instrument (Roche Diagnostics). Reagent kits
suitable for the extraction of viral RNA from serum and
plasma as recommended by the instrument manufacturer
Passing-Bablok regression analysis of SARS-CoV RNA con- centrations in (A) transport medium and (B) serum extracted  by the automated and manual methods Figure 1
Passing-Bablok regression analysis of SARS-CoV 
RNA concentrations in (A) transport medium and 
(B) serum extracted by the automated and manual 
methods. The regression line is indicated by the solid line, 
with the confidence intervals marked as dashed lines. The 
identity line (x = y) is indicated as the dotted line. TM: trans-
port medium.BMC Infectious Diseases 2006, 6:20 http://www.biomedcentral.com/1471-2334/6/20
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were evaluated. As the extraction procedure should con-
form to the biosafety practices recommended by the
World Health Organization [10], a modified protocol
which incorporates an external lysis processing step for
the MagNA Pure LC total nucleic acid large volume kit
(Roche Diagnostics) was developed. The World Health
Organization recommends that nucleic acid extraction
procedures for SARS-CoV involving untreated specimens
should first be performed under biosafety level 2 facilities
with additional level 3 work practices [10]. After the viral
particles had been lysed or inactivated, the specimens
could be handled according to standard level 2 practices.
We showed that the use of the large volume kit resulted in
better analytical sensitivity when compared with the total
nucleic acid kit as evident by the higher rates of positive
detection among samples containing low concentrations
of SARS-CoV. Furthermore, the MagNA Pure LC system
was shown to be free from problems of carry-over con-
tamination.
The automated extraction method involving the use of the
large volume kit with the external lysis procedure was fur-
ther compared with the quantitative performance of a pre-
viously described manual viral RNA extraction method
based on the use of the QIAamp viral RNA mini kit (Qia-
gen). Viral RNA extracted from the automated method led
to SARS-CoV concentrations that were consistently lower
than that extracted by the manual method across a wide
range of SARS-CoV concentrations in both transport
medium and serum. Furthermore, better detection rates
were observed for serum containing low concentrations of
SARS-CoV when extracted by the manual method in com-
parison with the automated method. The manual method
also contributed to better overall analytical precision as
evident by the lower coefficients of variation.
Conclusion
We have developed a modified protocol based on the use
of the MagNA Pure LC large volume kit (Roche Diagnos-
tics) which is more sensitive than the predefined external
lysis protocol of the MagNA Pure LC total nucleic acid kit
(Roche Diagnostics). Albeit the convenience and poten-
tial improvement in throughput offered by an automated
protocol, our evaluation revealed that the automated viral
RNA extraction protocol is less sensitive, less precise and
produced quantitative results that were consistently lower
than those of the column-based manual extraction
method. Though the reasons for the observed differences
in kit performance is not known at present, we recom-
mend the use of the column-based manual RNA extrac-
tion method as the diagnostic performance of the serum
SARS-CoV RNA quantitative RT-PCR test [4,5] is critically
associated with the analytical sensitivity contributed both
by the RNA extraction and RT-PCR components of the
test,. Furthermore, as it has been previously shown that
the serum SARS-CoV concentration has prognostic impli-
cations [4] and serial assessment is useful for the monitor-
ing of patient progress [5,6], the superior quantitative
performance and precision of the column-based extrac-
tion method are additional features that favour its use
over the automated protocol.
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Table 1: Analytical sensitivity and precision comparisons of the manual and automated methods.
Sensitivity comparison Precision comparison
SARS-CoV RNA Concentration (copies/mL) 10 102 103 103 105
mean S.D. CV (%) mean S.D. CV (%)
Automated 1/10a 7/10 10/10 349 268 76.9 35052 17892 51
Manual 4/10 9/10 10/10 1539 697 45.3 83591 39606 47.4
anumber of replicates with positive detection of SARS-CoV RNA.
S.D. denotes standard deviation and CV denotes coefficient of variation.Publish with BioMed Central    and   every 
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